CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187
http://doi.org/10.5281/zenodo.4399417

Avalable online at: http://www.iajps.com *Research Article*

MODE OF ACTION OF METFORMIN IN TYPE 2 DIABETES

[1]Dr. Aqsa Khalid, [2]Dr Uqba Afzal, [3]Kausar Mir Janan

[1]Allied Hospital, Faisalabad Medical University.
[2]Allied Hospital, Faisalabad Medical University.
[3]Rashid Latif Medical Complex, Lahore

Article Received: October 2020 **Accepted:** November 2020 **Published:** December 2020

Abstract:

Against hyperglycemic specialists, the biguanide metformin is the most known and effective, highlights as first-line pharmacologic treatment for type 2 diabetes, adequacy and bearableness of which are all around tried, finished up with wellbeing and moderate. In contrast to the sulfonylurea and insulin, metformin isn't related with weight gain or it is very cordial to patients however its mechanism of action has been hard to pinpoint.

This study will center to investigate all the degree of proposed mechanism alongside novel selected in the field of medicine.

Corresponding author:

Dr. Aqsa Khalid.,

Allied Hospital, Faisalabad Medical University.

QR code

Please cite this article in press Aqsa Khalid et al, ***Mode Of Action Of Metformin In Type 2 Diabetes.,*** *Indo Am. J. P. Sci, 2020; 07(12).*

INTRODUCTION:

Today's modernized urban society has a general issue known as diabetes type 2 mellitus that involve anomalies in insulin action, especially opposition [1] compares to raised blood glucose level for which hostile to hyperglycemia, broadly recommended is metformin, that reduces blood glucose level without expanding insulin discharge, and consequently at some point named as an insulin sensitizer [2]. Metformin indicated valuable impacts in type 2 diabetes, including weight reduction, improved lipid profiles, and upgraded endothelial capacity [3] Thus, metformin is presented for use in insulin-safe state even before the advancement of hyperglycemia [4]. It is reported that pace of hepatic glucose production was twice as high in diabetics than in controls and treatment with metformin reduced the pace of production by 24%, and fasting plasma glucose focus by 30%, additionally the pace of gluconeogenesis is multiple times higher in diabetics which is brought down by metformin by, taking everything into account metformin brings down the pace of endogenous glucose production by various pathways including lessened gluconeogenesis [5,6,7].

Literature search strategies

The current study is based on the analyses of previous studies. The researches included in this article belonged to many international bibliographies, including the ones who had an emphasis on metformin and the management of diabetes type 2. These sources included, webmd, Medscape, PubMed etc.

Selective Site of action of metformin

In both animals and human beings, pharmacokinetics of metformin is generally dictated by its dynamic through significant natural feline particle transporters[8] across the epithelium and subsequently decide paces of assimilation (plasma layer monoamine carrier (PMAT) and natural cation carrier (OCT3), they transport metformin into hepatocytes (OCT1) and from hepatocytes into the bile (multidrug and harmful compound expulsion [MATE] 1) and, at last, into the renal rounded epithelial cells (OCT2) and into the renal tubule (MATE2) [9]. Oct1 (otherwise called Slc22a1) mice show reduced adequacy of Metformin [10] and this work has set up a significant job for OCT1 in metformin admission and augment the special job of the liver as the essential site of action for metformin, summing up the impact via ingestion through the upper small digestive system gathered in enterocytes and then to hepatocyte therefore causes uninhibitedly, and is disposed of, with no modification by the kidneys [11, 12]. The particular impacts of metformin in hepatocyte is clarified on the premise that erasure of the OCT1 quality in mouse significantly reduces metformin intake in hepatocytes and humans conveying a debilitated impact of metformin in bringing down blood glucose [13], overwhelming articulation of the natural cation carrier 1 (OCT1),is available in the hepatocyte cell (Fig.1) that encourage cell take-up of Metformin [14].

Despite the fact that the atomic characteristics of metformin was tricky, Zhou et al. detailed that AMP-initiated protein kinase (AMPK) was exclusively connected with the pleiotropic actions of Metformin [15]. Intracellular vehicle is intervened by various isoforms of the natural cation carriers (OCT) (for example OCT1 in liver or OCT2 in kidney). Once inside the cytosolic compartment, mitochondria then establish the essential objective of metformin to repress mitochondrial respiratory-chain explicitly at the unpredictable 1 level without influencing some other strides of the mitochondrial apparatus. This remarkable property of the drug prompts a diminishing in NADH oxidation, proton siphoning across the internal mitochondrial layer and oxygen utilization rate, prompting bringing down of the proton gradient ($\Delta\phi$) and at last to a reduction in proton-driven synthesis of ATP from ADP and inorganic phosphate (Pi).

Metformin and AMPK

It has been shown that 5′AMP-actuated protein kinase (AMPK) fill in as sensor of cell energy status and is enacted in circumstance of high energy phosphate exhaustion, for example, in muscle contraction during activity and hypoxia, going about as a person of metformin in hepatocytes has been viewed as a significant sign in smothering lipogenesis and prompting unsaturated fat oxidation [16], accordingly decreasing action of acetyl-CoA carboxylase and bringing down articulation of a lipogenic record factor just as restraining hepatic gluconeogenesis. Surely plasma glucose–bringing down action isn't altogether reliant on insulin yet in addition practice causes an expansion of glucose take-up in the skeletal muscle of diabetic and nondiabetic subjects through the movement of GLUT-4 to cell films. This movement of GLUT-4 is interceded through insulin-free phosphorylation and actuation of AMPK [19-19]. Hence, this enzyme is viewed as a wonderful pharmacological objective in type 2 DM.

Metformin as an Insulin Sensitizer

Metformin brings down blood glucose focuses in

T2D without causing obvious hypoglycemia, known as an insulin sensitizer prompting reduction in insulin opposition and critical abatement of plasma fasting insulin level, credited of its constructive outcomes on insulin receptor articulation and tyrosine kinase activity, on phosphorylation of IR and IRS-1 by 100 and 90% separately interestingly insulin reduces phosphatidyl inositol 3-kinase (PI 3-kinase) action while metformin reestablished PI 3-kinase action in insulin-safe myotubes alongside basal actuation of p38 yet insulin didn't further invigorate p38 enactment in metformin treated cells. Since the impact of metformin on glucose take-up related to p38 MAPK initiation, proposing the potential job p38 in glucose take-up, exhibiting the immediate insulin sharpening action of metformin on skeletal muscle cell [20, 21].

An investigation of metformin treated liver cells exhibited that the mechanism of action of metformin in liver includes IR (1 miniature g/ml, metfor) tyrosine phosphorylation followed by specific IRS-2 actuation, and expanded glucose take-up through expanded GLUT-1 of every a focus subordinate way, impact of which is totally hindered by an IR inhibitor additionally basal IRS-2 mRNA, record was up-controlled by metformin likewise within the sight of insulin initiated Akt ,subject to phosphoinositide-3 kinase, considerably strengthen the insulin-animated movement of Glut-4 carriers from the cytosol to the layer [22].

Metformin and Mitochondrial Enzyme

In a progression of extensive new examination, Madiraju and associates [23], showed that imbuement of metformin to the test rodent precisely in the convergence of restorative reach exactly reduced endogenous glucose production bringing down the plasma glucose levels subsequently raising plasma lactate and glycerol levels, without changing hepatic gluconeogenic quality articulation or cell energy charge.[23] Furthermore, the outcomes compellingly reported that metformin specifically represses the mitochondrial isoform of glycerophosphate dehydrogenase, an enzyme that catalyzes the transformation of glycerophosphate to dihydroxyacetone phosphate (DHAP), in this way moving a couple of electrons to the electron transport chain causing a reduction in cytosolic DHAP and an ascent in the cytosolic NADH–NAD proportion, diminishing the transformation of lactate to pyruvate and lessening the utilization of glycerol and lactate as gluconeogenic antecedents to glucose, controlling hepatic gluconeogenesis, consequently developing of glycerol and lactate levels in plasma. Long time metformin dosing recreates these corresponding changes in the redox state, while expanding cytosolic redox and diminishing mitochondrial redox states ,consequently mitochondria gets oxidized comparative with cytoplasm [23]also study exhibited antisense oligonucleotide knockdown of hepatic mitochondrial glycerophosphate dehydrogenase in rodents brought about an aggregate like ongoing metformin treatment, and annulled metformin-intervened increments in cytosolic redox express, These discoveries were duplicated in entire body mitochondrial glycerophosphate dehydrogenase lab mice, the aftereffects of which are significant for the suggestion in restraint of endogenous glucose production to comprehend the mechanism of metformin's blood glucose bringing down impacts and give another helpful objective to type 2 diabetes [23, 24].

Metformin and Irisin

Irisin is a novel myocyte secreted hormone expected to be an ideal restorative objective of metformin free of AMPk enacted pathway in type 2 DM as an examination demonstrated irisin treatment reduced body weight and blood glucose in metformin-treated db/db mice,[24] showing metformin impact to upregulate irisin forerunner FNDC5 mRNA/protein articulation in muscle and improve irisin discharge autonomous from AMPK flagging pathway recommending novel mechanism of metformin.

Metformin as a Glucagon Antagonist

The liver is a fundamental organ that store glycogen and produce glucose later to the cerebrum during fasting particularly by the impact of hormone glucagon ,the failure of insulin to smother hepatic glucose yield is a significant etiological factor in the hyperglycemia said to be given insulin obstruction or type 2 diabetes mellitus (T2DM) [25, 26], metformin ,the most often endorsed drug for T2DM, recommended mechanism was it reduces glucose synthesis through actuation of the enzyme AMP-initiated protein kinase (AMPK) has as of late been genuinely tested in a changed investigation [27], and subsequently novel mechanism by which metformin alienates the action of glucagon is advanced in which fasting glucose levels is reduced by hindering adenylate cyclase, subsequently lifting intracellular AMP hence decreasing degrees of cyclic AMP and protein kinases A (PKA) movement, repeal phosphorylation of basic protein focuses of PKA, and square glucagon-subordinate glucose yield in this way restraint of liver glucose production, from hepatocytes, the free of AMPK, proposing new way to deal with the improvement of antidiabetic drugs [28, 29].

Metformin Inhibit Glucagon Signaling

A conceivable atomic mechanism of action currently rises out of late discoveries that place metformin to limit energy homeostasis and appeared to actuate a gentle and transient hindrance of the mitochondrial respiratory chain complex 1 that decline hepatic energy states and enacts the AMP-initiated protein kinase (AMPK), a cell metabolic calibrator (sensor), and gives a for the most part acknowledged mechanism to metformin action on hepatic gluconeogenic program [30, 31]. Nonetheless, this method of action by metformin has as of late been tested by mutational analyses, proof demonstrated that metformin-instigated restraint of hepatic glucose yield is interceded by reducing cellular energy charge instead of direct hindrance of gluconeogenic quality articulation. Moreover, late information upholds a novel mechanism of action of metformin including opposition of glucagon flagging pathways by instigating the collection of AMP, which restrains adenylate cyclase and reduced degrees of cAMP. Since both glycogenolysis and gluconeogenesis are controlled during the fasting state partially by the hormone glucagon, whose strange emission in T2DM is a main consideration in the pathophysiology of hyperglycemia, metformin creates its belongings by hindering glucagon flagging pathways [32-37], the hepatocyte plasma layer receptor get signal from the hormone that prompts enactment of adenylyl cyclase (AC), producing the second courier cyclic AMP (cAMP), and animating protein kinase A (PKA), in this way phosphorylates target proteins that work in show to build hepatic glucose yield [38], endogenous P site ligand (recommended to be AMP) particles containing an adenine moiety ties to the 'P-site' of adenylyl cyclase and repress its movement [39]. Despite the fact that the, the physiological or pharmacological importance of this administrative occasion has not recently been noticed [40-42], restorative degrees of metformin instigate a gentle vigorous pressure in hepatocytes, bringing about an expansion in AMP fixation to levels prepared to do straightforwardly hindering adenylyl cyclase. Various investigations recommend that the P site of adenylate cyclase may speak to a novel objective for the improvement of therapeutics for the treatment of insulin opposition and T2DM [43-48].

CONCLUSION:

Metformin is the fundamental treatment for diabetes mellitus since numerous years; the away from of action stayed not well characterized. In any case, proposed fundamental impact of this drug is to diminish hepatic glucose production through a gentle restraint of the mitochondrial respiratory-chain complex 1 that outcomes into transient reduction in cell energy status advancing enactment of AMP (lively sensor) otherwise called AMPK. Along these lines, enacted AMPK is accepted to advance transcriptional restraint of hepatic gluconeogenic quality and thus gluneo-genesis. Hindrance of hepatic glucose production by metformin is safeguarded in liver-explicit AMPK knockout mice firmly propose that other mechanism(s) are included, hence the abatement in hepatic energy status following restraint of the respiratory-chain complex 1 by metformin is likely the focal clarification for the intense reduction of hepatic gluconeogenesis by the drug. Furthermore, AMPK-subordinate mechanisms connected to the hepatic lipid digestion are likewise proposed, quite for clarifying its useful impact on insulin resistance, prompting the standardization of blood glucose levels, The information picked up from analyzing the essential mechanisms of metformin's novel method of action can assist us with growing new helpful drugs for the treatment of this unpleasant illness, some other proof clarifies restricting the action of glucagon, recommending the hindrance of mitochondrial complex I brings about deficient cAMP and protein kinase A motioning in light of glucagon. Additionally, incitement of 5′-AMP-enacted protein kinase, albeit superfluous for the glucose-bringing down impact of metformin, gives insulin affectability, predominantly by adjusting lipid digestion accordingly comprehension of the anti-gluconeogenic action of metformin in the liver and the ramifications of new revelations of metformin focuses for the treatment of diabetes mellitus will be gainful to the T2DM persistent.

REFERENCES:

1. El-Atat F, McFarlane SI, Sowers JR: Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management. Curr Hypertens Rep, 2004; 6 :215 –223.
2. Hundal RS, Inzucchi SE: Metformin: new understandings, new uses. Drugs, 2003; 63:1879 – 1894.
3. Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med, 2004; 256:1 – 14.
4. Davies MJ, Tringham JR, Troughton J, Khunti KK: Prevention of type 2 diabetes mellitus: a review of the evidence and its application in a UK setting. Diabet Med, 2004; 21:403 –414.
5. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI.Mechanism by which metformin

reduces glucose production in type 2 diabetes.Diabetes, 2000; 49(12):2063-9.
6. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI.Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.N Engl J Med , 1998; 338(13):867-72.
7 Cheng JT, Huang CC, Liu IM, Tzeng TF, Chang CJ.Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats.Diabetes, 2006;55(3):819-25.
8. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res, 2007; 24:1227–1251.
9. Rena G, Pearson ER, Sakamoto K. Molecular action and pharmacogenetics of metformin: current understanding of an old drug. Diabetes Management, 2012; 2:439–452.
10. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest, 2007; 117:1422–1431.
11. Bailey CJ, Turner RC. Metformin. N Engl J Med, 1996; 334:574-579.
12.. Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care, 2004; 27:1349-1357.
13. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica, 1994; 24:49–57.
14. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest, 2007; 117:1422–1431.
15. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk- Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 2001; 108:1167– 1174
16. Vinita Takiar,Saori Nishio, Patricia Seo-Mayer,J. Darwin King, Jr etal.Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci, 2011; 108(6): 2462–2467.
17. Kennedy JW, Hirshman MF, Gervino EV, Ocel JV, Forse RA, Hoenig SJ, Aronson D, Goodyear LJ, Horton ES: Acute exercise induces GLUT4 translocation in skeletal muscle of normal human subjects and subjects with type 2 diabetes. Diabetes, 1999;48 :1192 –1197.
18. Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, Winder WW: 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes,1999;48:1667 –1671.
19. Hayashi T, Hirshman MF, Kurth EJ, Winder WW, Goodyear LJ: Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes, 1998.47 :1369 –1373.
20. Gunton JE, Delhanty PJ, Takahashi S, Baxter RC.Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2.J Clin Endocrinol Metab, 2003; 88(3):1323-32.
22) Kumar N, Dey CS.Metformin enhances insulin signalling in insulin-dependent and-independent pathways in insulin resistant muscle cells.Br J Pharmacol, 2002; 137(3):329-36.
23) Rice S, Pellatt LJ, Bryan SJ, Whitehead SA, Mason HD.Action of metformin on the insulin-signaling pathway and on glucose transport in human granulosa cells.J Clin Endocrinol Metab, 2011;96(3):427-35.
24) Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature, 2014; 510:542-546.
24. Li DJ, Huang F, Lu WJ, Jiang GJ, Deng YP, Shen FM.Metformin promotes irisin release from murine skeletal muscle independently of AMPK ctivation.Acta Physiol (Oxf), 2014 ; 10:12421.
25. DeFronzo RA, Simonson D, Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin- dependent) diabetes mellitus. Diabetologia, 1982; 23:313–9.
26. Postic C, Dentin R, Girard J. Role of the liver in the control of carbohydrate and lipid homeostasis. Diabetes Metab, 2004;30:398–408.
27. Nathan DM, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2009; 32:193–20.
28. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.Journal of Clinical Investigation. J Clin Invest, 2010; 120(7): 2355–2369.
29. Inzucchi SE, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med, 1998; 338:867–72.

30. Goodarzi MO, Bryer-Ash M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab, 2005;7:654–65.
31. El-Mir MY, et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem, 2000; 275:223–8.
32. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J,2000; 348:607–14.
33. Shaw RJ , et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 2005; 310:1642–6.
34. Zhou G, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 2001; 108:1167–74.
35. Revisiting the mechanisms of metformin action in the liver.Viollet B, Foretz M. Ann Endocrinol (Paris)**,** 2013; 74(2):123-9.
36. D'Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab, 2010;13(Suppl 1):126–32.
37. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab, 2003; 284:E671–8.
38. Unger RH, Cherrington AD.Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover.J Clin Invest, 2012;12 2(1):4-
12.
39. Tucker GT, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol, 1981; 12:235–46.
40. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica, 1994;24:49–57.
41. Allen MD, Zhang J. Subcellular dynamics of protein kinase A activity visualized by FRET-based reporters. Biochem Biophys Res Commun,2006;348:716–21.
42. Fain JN, Pointer RH, Ward WF. Effects of adenosine nucleosides on adenylate cyclase, phosphodiesterase, cyclic adenosine monophosphate accumulation, and lipolysis in fat cells. J Biol Chem, 1972; 247:6866–72.
43. Blume AJ, Foster CJ. Mouse neuroblastoma adenylate cyclase. Adenosine and adenosine analogues as potent effectors of adenylate cyclase activity. J Biol Chem1, 975; 250:5003–8.
44. Londos C, Preston MS. Regulation by glucagon and divalent cations of inhibition of hepatic adenylate cyclase by adenosine. J Biol Chem, 1977; 252:5951– 6.
45. Johnson RA, Yeung SM, Stubner D, Bushfield M, Shoshani I. Cation and structural requirements for P site-mediated inhibition of adenylate cyclase. Mol Pharmacol, 1989; 35:681–8.
46. Berglund ED, et al. Hepatic energy state is regulated by glucagon receptor signaling in mice. J Clin Invest,2009;119:2412–22. 23.
47. Fain JN, Malbon CC. Regulation of adenylate cyclase by adenosine. Mol Cell Biochem, 1979; 25:143–69.
48. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F.Cellular and molecular mechanisms of metformin: an overview.Clin Sci (Lond), 2012; 122(6):253-70.